ReviewACS omega2025
GPR17 in Glioblastoma: Structure, Ligand Interactions, and Therapeutic Targeting.
Review in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- GPR17 Suppresses Triple-Negative Breast Cancer Progression and Serves as an Independent Prognostic Biomarke.World journal of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
G protein-coupled receptor 17 (GPR17) is a crucial protein encoded by the GPR17 gene, which belongs to the G protein-coupled receptor (GPCR) family. It serves a pivotal function in cellular responses to various stimuli. GPR17 is found in various organs, including the brain, spinal cord, kidneys, liver, and immune cells. It is especially prevalent in oligodendrocytes, underscoring its significance in myelination. GPR17 is involved in myelination, inflammation, and neuroprotection. Recent studies highlight the therapeutic potential of targeting GPR17 in glioblastoma, a highly aggressive brain cancer, as it is overexpressed in tumor tissues and plays a critical role in tumor progression and invasion. Understanding the structure of GPR17 and its interactions with ligands and functional signaling pathways is crucial for developing targeted therapeutics for conditions involving myelin degradation, neuroinflammation, and immune dysregulation. To guide this exploration, this review is organized into distinct sections covering the sequence and structural features of GPR17, its natural and synthetic ligands, its role in glioblastoma progression, its associated signaling pathways, and the potential of using GPR17 as a therapeutic target. Each section in the review consolidates current findings to offer an integrated view of GPR17 biology and its translational relevance in oncology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.